Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
, 8 (5), 299-311

A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma With High Tumor Burden: Initial Lenvatinib Therapy With Subsequent Selective TACE

Affiliations
Editorial

A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma With High Tumor Burden: Initial Lenvatinib Therapy With Subsequent Selective TACE

Masatoshi Kudo. Liver Cancer.

Conflict of interest statement

Masatoshi Kudo received lecture fees from Bayer, Eisai, MSD, and Ajinomoto, research grants from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, AbbVie, Medico's Hirata, Astellas Pharma, and Bristol-Myers Squibb, and advisory consulting fees from Kowa, MSD, Bristol-Myers Squibb, Bayer, Chugai, Taiho, Eisai, and Ono Pharmaceutical.

Similar articles

See all similar articles

Publication types

LinkOut - more resources

Feedback